Reply To:
Name - Reply Comment
Last Updated : 2024-04-19 11:48:00
AFP: US federal regulators have given the green light to French pharmaceutical company Sanofi and its US partner Regeneron to market a drug to treat the chronic inflammatory condition, rheumatoid arthritis.
The Food and Drug Administration authorisation had been delayed over “deficiencies” found by the regulatory agency during an inspection of the Sanofi manufacturing site in the Normandy region of France.
The drug sarilumab which will be marketed under the brand name Kevzara could generate US$1.8 billion in sales by 2020, and is considered by Sanofi as a future flagship product to support long-term growth.
Canadian regulators made a similar ruling in February. The European Medicines Agency gave the drug a favorable opinion in April, according to Sanofi, prior to a final European Commission decision expected in the coming months.
In Europe, some 2.9 million people suffer from rheumatoid arthritis, a painful autoimmune disorder that causes joint pain, swelling, stiffness and fatigue.
Treatments that already exist for the condition include the anti-inflammatory Humira, from the US company AbbVie, as well as biosimilars -- products that mimic the effects of more costly biologic drugs made from living cells.
Add comment
Comments will be edited (grammar, spelling and slang) and authorized at the discretion of Daily Mirror online. The website also has the right not to publish selected comments.
Reply To:
Name - Reply Comment
On March 26, a couple arriving from Thailand was arrested with 88 live animal
According to villagers from Naula-Moragolla out of 105 families 80 can afford
Is the situation in Sri Lanka so grim that locals harbour hope that they coul
A recent post on social media revealed that three purple-faced langurs near t